In accordance with a settlement agreement, Teva Pharmaceuticals has launched its generic for Bristol Myers Squibb’s Revlimid® (lenalidomide) in the United States. The FDA approved the generic on May 21, 2021.

• Like brand name Revlimid, Teva’s generic is indicated to treat:
  • Multiple myeloma when used in combination with
  • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality, with or without additional cytogenetic abnormalities.
  • Mantle cell lymphoma that has relapsed or progressed following two prior therapies, one of which included bortezomib.
• Unlike Revlimid, the generic is not currently FDA approved for:
  • Use as a multiple myeloma maintenance therapy in patients who have undergone autologous hematopoietic stem cell transplantation.
  • Use in combination with a rituximab product to treat follicular lymphoma or marginal zone lymphoma in patients who have received prior treatment.
• Teva’s generic is available in 5mg, 10mg, 15mg, and 25mg capsules. Revlimid is available in two additional dosage strengths (2.5mg and 20mg capsules) for which no generic is currently available on the S. market. Recommended dosing for both the brand name and generic product is based on the indication.
• Revlimid has a wholesale acquisition cost (WAC) of $17,497.73 per four-week supply compared to $15,118.04 for Teva’s generic.